Advice
following a full submission:
ruxolitinib (Opzelura®) is not recommended for use within NHSScotland.
Indication under review: for the treatment of non-segmental vitiligo (NSV) with facial involvement in adults and adolescents from 12 years of age.
In two randomised, double-blind phase III studies, there was significantly greater facial repigmentation following 24 weeks of treatment with ruxolitinib cream compared with vehicle cream in patients with non-segmental vitiligo.
The submitting company did not present a sufficiently robust economic analysis to gain acceptance by SMC.
Medicine details
- Medicine name:
- ruxolitinib (Opzelura)
- SMC ID:
- SMC2634
- Indication:
For treatment of non-segmental vitiligo with facial involvement in adults and adolescents from 12 years of age
- Pharmaceutical company
- Incyte Biosciences UK Ltd
- BNF chapter
- Skin
- Submission type
- Full
- Status
- Not recommended
- Date advice published
- 13 May 2024